A decrease in erythrocyte electrophoretic mobility serves as an important diagnostic marker of pathological conditions associated with impaired gas exchange, microcirculation, and tissue trophism, often leading to systemic hypoxia and deterioration of the patient's clinical status. This study investigates the potential of magnetite nanoparticles (MCS-B) to modulate these properties in a targeted and controlled manner. A novel approach is proposed to enhance erythrocyte electrophoretic mobility in patients with toxemia through treatment with magnetite nanoparticles. In vitro experiments demonstrated a statistically significant (p 

Andrey N. Belousov, MD, PhD, Professor - a Ukrainian medical scientist and pioneer in nanotechnology, who developed the world’s first biocompatible nanomedical drugs (Micromage-B, MCS-B, ICNB), officially registered and introduced into clinical practice since 1998. His work established a translational foundation for medical nanotechnology, linking fundamental biophysics with clinical applications in detoxification, hemocorrection, and neuroprotection. The published more 360 scientific works on results application of nanotechnology preparation in experimental and practical medicine. At now Andrey Belousov - the Head of Laboratory Applied Nanotechnologies, Professor of Kharkiv National Medical University, Ukraine.